EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Applying the hallmarks of artificial intelligence to genitourinary medical oncology: an evidence-maturity framework for precision cancer care

Firas Hatoum, Sola Maria Saleh, Mohamad Sadek Zoghbi, Arielle Pekofsky, Nadine Mahmoud, Jeffrey S. Johnson, Justin W. Miller, Casey Le, Hatem Hassanein, Barbara Broome, Raji Shameem, Philippe E. Spiess und 1 weitere

Frontiers in Oncology · 09.11.2026 · 16

DOI: 10.3389/fonc.2026.1961809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Firas Hatoum und 12 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) is increasingly reshaping genitourinary (GU) medical oncology across the cancer-care continuum. In this structured narrative review, we apply the ten-hallmark precision-oncology taxonomy proposed by Chang et al. to GU malignancies. We further define GU-specific hallmark boundaries and introduce study-design and validation descriptors that span proof-of-concept, internal and external validation, prospective clinical evaluation, and prospective interventional evaluation, while distinguishing evidence derived from randomized trials. Across prostate, urothelial, and kidney cancers, AI has shown promising technical performance in imaging, pathology, molecular inference, and outcome modeling. General-oncology trial-matching benchmarks offer additional research opportunities, although evidence remains uneven. Among the examples reviewed, validation designs highly vary, and strong discrimination should not be interpreted as evidence of clinical benefit. We therefore emphasize cohort size, validation design, head-to-head comparator evidence, calibration when reported, and implementation considerations including regulation, model drift, fairness, clinician oversight, cybersecurity, workflow integration, and cost. The next phase of AI in GU oncology will depend on demonstrating incremental clinical utility and patient benefit, not only higher accuracy.

Zitieren

APA

Hatoum, F., Saleh, S. M., Zoghbi, M. S., Pekofsky, A., Mahmoud, N., Johnson, J. S., Miller, J. W., Le, C., Hassanein, H., Broome, B., Shameem, R., Spiess, P. E., & Chahoud, J. (2026). Applying the hallmarks of artificial intelligence to genitourinary medical oncology: an evidence-maturity framework for precision cancer care. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1961809

Vancouver

Hatoum F, Saleh SM, Zoghbi MS, Pekofsky A, Mahmoud N, Johnson JS, et al. Applying the hallmarks of artificial intelligence to genitourinary medical oncology: an evidence-maturity framework for precision cancer care. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1961809

BibTeX
@article{Hatoum2026,
  author = {Hatoum, Firas and Saleh, Sola Maria and Zoghbi, Mohamad Sadek and Pekofsky, Arielle and Mahmoud, Nadine and Johnson, Jeffrey S. and Miller, Justin W. and Le, Casey and Hassanein, Hatem and Broome, Barbara and Shameem, Raji and Spiess, Philippe E. and Chahoud, Jad},
  title = {Applying the hallmarks of artificial intelligence to genitourinary medical oncology: an evidence-maturity framework for precision cancer care},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1961809}
}
Kostenlos starten →